Clarifying and testing the in vivo significance of these mechanisms is translationally relevant given proposed COVID-19 therapies utilizing recombinant soluble ACE2 or blocking antibodies to competitively inhibit viral spread [9–13]. The gene discussed is ACE2; the disease is COVID-19.